Wealth Enhancement Advisory Services LLC Has $96,000 Stake in Ironwood Pharmaceuticals, Inc. $IRWD

Wealth Enhancement Advisory Services LLC raised its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 425.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 125,460 shares of the biotechnology company’s stock after buying an additional 101,574 shares during the period. Wealth Enhancement Advisory Services LLC owned about 0.08% of Ironwood Pharmaceuticals worth $96,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Exchange Traded Concepts LLC increased its holdings in shares of Ironwood Pharmaceuticals by 173.5% in the first quarter. Exchange Traded Concepts LLC now owns 178,523 shares of the biotechnology company’s stock valued at $262,000 after purchasing an additional 113,245 shares in the last quarter. Cerity Partners LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the first quarter valued at approximately $142,000. CWM LLC increased its holdings in shares of Ironwood Pharmaceuticals by 801.1% in the first quarter. CWM LLC now owns 57,001 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 50,675 shares in the last quarter. Allianz Asset Management GmbH increased its holdings in shares of Ironwood Pharmaceuticals by 411.5% in the first quarter. Allianz Asset Management GmbH now owns 293,100 shares of the biotechnology company’s stock valued at $431,000 after purchasing an additional 235,800 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd increased its holdings in shares of Ironwood Pharmaceuticals by 162.6% in the first quarter. Y Intercept Hong Kong Ltd now owns 39,782 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 24,635 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on IRWD shares. Zacks Research raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Wall Street Zen raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 9th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ironwood Pharmaceuticals in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $4.94.

Ironwood Pharmaceuticals Stock Down 10.5%

Shares of NASDAQ IRWD opened at $1.59 on Monday. The company’s fifty day moving average is $1.25 and its 200-day moving average is $0.95. The stock has a market cap of $257.46 million, a price-to-earnings ratio of -31.69 and a beta of 0.30. Ironwood Pharmaceuticals, Inc. has a twelve month low of $0.53 and a twelve month high of $5.13.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported $0.14 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. The business had revenue of $85.24 million for the quarter, compared to analysts’ expectations of $62.02 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current fiscal year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.